Pembrolizumab (anti-PD-1)

製品コード：A2005         Batch: A200506

印刷

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

製品説明

CAS No. 1374853-91-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 6.1mg/ml
Endotoxin Level ＜1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] PubMed: 38374347
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation [ Cell Mol Immunol, 2024, 21(1):60-79] PubMed: 38062129
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] PubMed: 38176728
[ BMC Cancer, 2024, ] PubMed: 38409035
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal [ Signal Transduct Target Ther, 2023, 8(1):312] PubMed: 37607946
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma [ J Exp Clin Cancer Res, 2023, 42(1):251] PubMed: 37759291
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] PubMed: 36799619
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] PubMed: 36799619
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis [ Respir Res, 2023, 24(1):279] PubMed: 37964265

人間や獣医の診断であるか治療的な使用のためにでない。